Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E127.74 EPS (ttm)4.02 Insider Own0.20% Shs Outstand103.69M Perf Week1.77%
Market Cap53.24B Forward P/E34.90 EPS next Y14.72 Insider Trans-39.07% Shs Float76.44M Perf Month-7.25%
Income460.60M PEG5.66 EPS next Q3.10 Inst Own73.70% Short Float4.64% Perf Quarter0.90%
Sales3.40B P/S15.68 EPS this Y-19.40% Inst Trans1.31% Short Ratio4.76 Perf Half Y24.48%
Book/sh32.45 P/B15.82 EPS next Y20.82% ROA11.30% Target Price617.48 Perf Year46.52%
Cash/sh5.83 P/C88.11 EPS next 5Y22.58% ROE16.10% 52W Range320.06 - 605.93 Perf YTD25.17%
Dividend- P/FCF- EPS past 5Y41.20% ROI12.50% 52W High-15.25% Beta0.83
Dividend %- Quick Ratio3.60 Sales past 5Y49.40% Gross Margin91.50% 52W Low60.44% ATR21.25
Employees2925 Current Ratio3.80 Sales Q/Q50.00% Oper. Margin31.20% RSI (14)39.60 Volatility4.63% 3.64%
OptionableYes Debt/Eq0.12 EPS Q/Q98.80% Profit Margin13.60% Rel Volume1.12 Prev Close536.70
ShortableYes LT Debt/Eq0.12 EarningsAug 04 BMO Payout0.00% Avg Volume746.00K Price513.50
Recom2.00 SMA20-8.05% SMA50-5.39% SMA2009.63% Volume833,108 Change-4.32%
Aug-31-15Downgrade Chardan Capital Markets Buy → Neutral $565
Aug-10-15Reiterated ROTH Capital Neutral $495 → $527
Aug-06-15Reiterated Argus Buy $560 → $660
Aug-05-15Reiterated UBS Sell $500 → $565
Aug-05-15Reiterated RBC Capital Mkts Outperform $570 → $665
Aug-05-15Reiterated Canaccord Genuity Buy $600 → $700
Aug-05-15Reiterated Barclays Equal Weight $460 → $595
Aug-04-15Reiterated Brean Capital Buy $525 → $659
Aug-03-15Reiterated Leerink Partners Outperform $559 → $630
Jul-27-15Reiterated RBC Capital Mkts Outperform $560 → $570
Jul-22-15Initiated Northland Capital Market Perform $560
Jul-20-15Reiterated RBC Capital Mkts Outperform $550 → $560
Jul-13-15Reiterated Deutsche Bank Buy $455 → $650
Jun-15-15Reiterated RBC Capital Mkts Outperform $543 → $550
Jun-10-15Reiterated Chardan Capital Markets Buy $560 → $565
May-20-15Reiterated Canaccord Genuity Buy $525 → $600
May-20-15Reiterated Argus Buy $500 → $560
May-19-15Reiterated Brean Capital Buy $507 → $525
May-15-15Reiterated JP Morgan Neutral $427 → $450
May-08-15Reiterated UBS Neutral $412 → $500
Aug-31-15 04:43PM  Medicines Co., Alnylam Jump Ahead In Cholesterol Race at Investor's Business Daily
04:20PM  Applied Genetic Meets Enrolment Milestone in XLRS Study
01:31PM  Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns
10:09AM  Regeneron: A Downgrade With a Positive Bias? at Barrons.com
09:30AM  Regeneron Announces Upcoming 2015 Investor Conference Presentations PR Newswire
09:20AM  Stock Futures Down, Off Lows; Medicines Co., Alnylam Spike at Investor's Business Daily
07:57AM  Regeneron Pharms downgraded by Chardan Capital Markets
Aug-29-15 08:02AM  4 IBD 50 Drugmakers Getting Lift From New Treatments at Investor's Business Daily
Aug-28-15 04:40PM  Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance
04:00PM  Exelixis Up on Swiss Approval of Advanced Melanoma Drug
03:34PM  Gilead & Amgen Account for Nearly 75% of the Biotech Profit Pool at Barrons.com
12:12PM  Amgen v. Regeneron: Everyone Wins? at Barrons.com
10:35AM  Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S.
08:37AM  Time to Buy Amgen After Newly Approved Drug? at TheStreet
Aug-27-15 09:10PM  Amgen wins approval for second biotech cholesterol drug
06:49PM  Amgen's Repatha OK'd With Similar Label To Praluent at Investor's Business Daily
05:17PM  FDA approves Amgen's cholesterol drug Repatha Reuters
02:31PM  Cholesterol drug wars
12:00PM  Regeneron Pharmaceuticals (REGN) Stock Is the 'Chart of the Day' at TheStreet
11:02AM  'We See Opportunity in Biogen, Gilead and Regeneron,' Morgan Stanley Says at Barrons.com
06:28AM  Cholesterol drug wars: Amgen
Aug-25-15 02:32PM  Stocks: Don't Kill Your Darlings at Barrons.com
02:09PM  9 Stocks Strong Enough To Weather This Storm at Barrons.com
12:15PM  Bouncing Biotech? 3 Stocks To Buy at Motley Fool
11:55AM  IBB ETF Pounded by Biotech and Pharma Subgroups in Early August
09:17AM  What Are IBB and XBIs Valuations?
06:40AM  4 Stocks to Sell Now, Until the Fed Acts at 24/7 Wall St.
Aug-24-15 11:26AM  A Buying Opportunity For Regeneron: RBC at Barrons.com
Aug-21-15 10:43AM  4 Reasons To Keep An Eye On Biotech Stock Celgene
Aug-20-15 05:54PM  Dividend cuts for big oil?
05:42PM  Cholesterol war heats up
05:00PM  3 ways to play biotech's beatdown
01:52PM  IBB Outperforms XBI: Top 10 Large-Cap Stocks
01:51PM  IBB and XBI Underperformed the Benchmark Indexes
11:06AM  Regeneron Outperforms with Better 2Q15 Results
11:02AM  This Is a Concern That Amgen Investors Shouldn't Take Lightly at Motley Fool
Aug-19-15 09:07AM  Regeneron Leads and Shire Dragged the Large-Cap Stocks
Aug-18-15 01:56PM  Esperion Therapeutics: Love and Hate at Barrons.com
11:22AM  Esperion Drug Update Gets Mixed Wall Street Reaction at Investor's Business Daily
09:56AM  IBB Fell by 3.62% in the Week Ending August 7
Aug-17-15 06:30PM  Facebook, EBay, Google Flex Renewed Tech Strength at Investor's Business Daily
08:02AM  Are the 3 Best-Performing Big-Cap Biotech Stocks of 2015 Still Worth Buying? at Motley Fool
Aug-14-15 10:30AM  Avalanche Biotechnologies (AAVL) Q2 Loss Narrows Y/Y
Aug-13-15 11:42AM  Payers Set To Play Hardball On PCSK9 Pricing: RBC at Investor's Business Daily
08:59AM  Looking for a Top Growth Stock? 3 Reasons Why Regeneron Pharmaceuticals (REGN) Is an Impressive Choice
Aug-12-15 09:30AM  Regeneron Pharmaceuticals, Oshkosh, Amgen and Caterpillar highlighted as Zacks Bull and Bear of the Day
09:01AM  Bull of the Day: Regeneron Pharma (REGN)
Aug-10-15 04:22PM  Netflix Price Target Hiked; Google, Twitter Are Buys at Investor's Business Daily
02:40PM  CVS, Express Scripts Pick Drugs to Restrict; Did Gilead's Sovalidi Make the Cut? at Barrons.com
12:24PM  Don't Give up on Biogen: Deutsche Bank Sees Fair Value at $400 at Barrons.com
08:20AM  3 Large Biotech Stocks to Buy Despite Higher Interest Rates Coming at 24/7 Wall St.
Aug-08-15 01:04PM  REGENERON PHARMACEUTICALS INC Financials
12:01PM  3 Top Biotech Stocks for High-Risk Investors at Motley Fool
Aug-07-15 10:55AM  Will Gilead Make 'Transformative Transaction'?
Aug-06-15 08:09PM  10-Q for Regeneron Pharmaceuticals, Inc. at Company Spotlight
04:13PM  These Two Biotechs Boast Big EPS Growth Rates at Investor's Business Daily
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Vertex, Regeneron, Baxalta and VIVUS - Press Releases
08:09AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Aug-05-15 07:00PM  Has Disney lost its magic?
06:56PM  Cramer: Commodity plays ready to shine at CNBC
04:30PM  Slowing iPhone Growth Hits Apple; Disney Downgraded at Investor's Business Daily
10:44AM  Biotech Stock Roundup: Baxalta Rejects Shire Bid, Amgen's Beat & Raise Quarter - Analyst Blog
08:03AM  Will Regeneron's New Drug Break The Bank? at Motley Fool
12:33AM  Bird in Regenerons Hand Is Enough at The Wall Street Journal
Aug-04-15 06:25PM  Stock Market Today - 08/04/15
06:12PM  Cramer: Why Apple is not for the squeamish at CNBC
06:00PM  Regeneron Surges On Strong Outlook, As Does Abiomed
04:24PM  Stocks Bleed More Red; Apple Weak Again, Suppliers Hit Too at Investor's Business Daily
03:25PM  Edited Transcript of REGN earnings conference call or presentation 4-Aug-15 12:30pm GMT
03:03PM  Evercore Breaks Down Regeneron's Q2 Report
02:14PM  Regeneron Tops 3 Med Stocks Moving Big On Earnings
01:36PM  Bird in Regeneron's Hand Is Enough at The Wall Street Journal
01:25PM  Technology, Semiconductor ETFs Slump On Apple's Plunge at Investor's Business Daily
01:05PM  Regeneron Pops On Upbeat Q2 at Barrons.com
01:03PM  Regeneron's Knock-out Quarter Could Be Just The Beginning at Motley Fool
12:39PM  Regeneron Raises Sales Forecast on Demand for Top Drug Eylea at Bloomberg
12:37PM  Regeneron, Abiomed Surge On Strong Quarters, Guidance at Investor's Business Daily
10:29AM  Cramer -- Dont Bet Against R.R. Donnelley & Sons or Regeneron at TheStreet
10:00AM  Regeneron Beats on Q2 Earnings, Eylea 2015 View Upped - Analyst Blog
09:23AM  Cramer's Mad Dash: RRD's 3-way split
09:19AM  Morning Movers: Futures Edge Lower, Coach, Regeneron Soar at Barrons.com
07:54AM  Early movers: AET, TIME, REGN, BABA, ADM & more at CNBC
07:38AM  Regeneron (REGN) Beats on Q2 Earnings, Updates 2015 View - Tale of the Tape
07:16AM  Regeneron Pharmaceuticals Profit Doubles at The Wall Street Journal
07:11AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financ
07:07AM  Q2 2015 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open
06:45AM  Regeneron tops Street 2Q forecasts
06:39AM  Drugmaker Regeneron's revenue jumps on Eylea sales
06:30AM  Regeneron Reports Second Quarter 2015 Financial and Operating Results PR Newswire
Aug-03-15 07:03PM  Markets find new sources of angst at CNBC
04:59PM  5 Biotechs With Catalysts Coming This Week
03:18PM  What to Watch in the Day Ahead - Tuesday, August 4 Reuters
02:18PM  Health, Consumer ETFs Holding IBD 50 Stocks Set To Report at Investor's Business Daily
01:05PM  5 Top Medical Stocks Reporting Earnings This Week at Investor's Business Daily
11:40AM  Regeneron Still Has Legs: Leerink Targets $630 a Share at Barrons.com
Aug-01-15 08:02AM  IBD 50: 10 Top Stocks Reporting Earnings This Week at Investor's Business Daily
Jul-31-15 06:59PM  Cramer Remix: If China falls, buy this stock at CNBC
06:09PM  Cramer game plan: Prep for sharp selloff next week at CNBC
06:00PM  Cramer: Keep one eye on earnings & the other on the big p...
04:24PM  Express Scripts excludes 20 more drugs from 2016 coverage Reuters
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company's trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has collaborations with Sanofi to discover, develop, and commercialize human monoclonal antibodies and antibody cancer treatments; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA, as well as with Avalanche Biotechnologies, Inc. to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Powchik PeterSVP Clinical Development & RegAug 14Sale573.3823,48513,465,86615,821Aug 17 04:01 PM
Powchik PeterSVP Clinical Development & RegAug 13Option Exercise117.3360,3617,082,07046,299Aug 17 04:01 PM
POON CHRISTINE ADirectorAug 12Sale564.1611263,186790Aug 12 04:45 PM
POON CHRISTINE ADirectorAug 11Option Exercise273.67470128,6251,125Aug 12 04:45 PM
GILMAN ALFRED GDirectorAug 06Option Exercise57.115,000285,55013,912Aug 07 06:15 PM
GILMAN ALFRED GDirectorAug 06Sale587.125,0002,935,6018,912Aug 07 06:15 PM
Terifay Robert JSVP CommercialAug 06Sale588.9713,4237,905,78123,293Aug 07 06:14 PM
Terifay Robert JSVP CommercialAug 05Option Exercise30.6332,500995,47552,529Aug 07 06:14 PM
Tessier-Lavigne MarcDirectorAug 05Option Exercise57.115,000285,5506,187Aug 05 08:55 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Option Exercise270.435,0001,352,1509,745Aug 05 08:58 PM
Landry Robert ESVP Finance & CFOAug 05Option Exercise272.704,0001,090,80011,099Aug 06 09:00 PM
Landry Robert ESVP Finance & CFOAug 05Sale592.844,0002,371,3507,099Aug 06 09:00 PM
Tessier-Lavigne MarcDirectorAug 05Sale590.265,0002,951,2751,187Aug 05 08:55 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Sale585.535,0002,927,6484,945Aug 05 08:58 PM
GOLDSTEIN JOSEPH LDirectorAug 04Sale586.002,0001,172,00014,000Aug 05 10:03 AM
GOLDSTEIN JOSEPH LDirectorJul 15Sale550.002,0001,100,00016,000Jul 15 04:09 PM
GOLDSTEIN JOSEPH LDirectorJun 22Sale526.852,0001,053,70018,000Jun 22 05:02 PM
SING GEORGE LDirectorMay 27Option Exercise19.695,00098,450117,772May 29 04:19 PM
SING GEORGE LDirectorMay 27Sale515.005,0002,575,000112,772May 29 04:19 PM
INGRAM ROBERT ALEXANDERDirectorMay 27Sale513.391,379707,9651,500May 27 04:02 PM
INGRAM ROBERT ALEXANDERDirectorMay 22Option Exercise293.536,6671,956,9656,667May 27 04:02 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Option Exercise174.0113,4642,342,90217,481May 26 04:31 PM
GOLDSTEIN JOSEPH LDirectorMay 22Sale514.284,0002,057,10020,000May 26 04:30 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Sale515.6013,0006,702,8004,481May 26 04:31 PM
BROWN MICHAEL SDirectorMay 15Option Exercise57.115,000285,5505,000May 18 04:50 PM
BROWN MICHAEL SDirectorMay 15Sale495.005,0002,475,0000May 18 04:50 PM
Landry Robert ESVP Finance & CFOApr 08Option Exercise272.7010,0002,727,00015,000Apr 09 04:03 PM
BAKER CHARLES ADirectorMar 25Option Exercise18.615,00093,05014,000Mar 26 04:20 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 25Option Exercise59.203,097183,34215,067Mar 26 04:21 PM
BAKER CHARLES ADirectorMar 25Sale454.965,0002,274,7859,000Mar 26 04:20 PM
Aberman Michael SSVP Strategy Investor RelationMar 24Sale478.994,8432,319,73812,498Mar 25 04:07 PM
Aberman Michael SSVP Strategy Investor RelationMar 18Sale465.003,4421,600,54222,498Mar 19 04:05 PM
Aberman Michael SSVP Strategy Investor RelationMar 17Option Exercise24.0011,398273,55229,998Mar 19 04:05 PM
Terifay Robert JSVP CommercialMar 17Sale451.0110,9934,957,90720,029Mar 18 06:03 PM
Terifay Robert JSVP CommercialMar 16Option Exercise30.6324,375746,60644,404Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Option Exercise59.2020,2811,200,63528,311Mar 17 04:57 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Sale450.0018,3118,239,95010,000Mar 17 04:57 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 27Sale416.243,0001,248,7204,481Feb 27 04:31 PM
Tessier-Lavigne MarcDirectorFeb 26Option Exercise50.913,000152,7304,187Feb 27 04:32 PM
Tessier-Lavigne MarcDirectorFeb 26Sale421.953,0001,265,8641,187Feb 27 04:32 PM
Aberman Michael SSVP Strategy Investor RelationFeb 24Sale418.483,3741,411,95218,600Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 24Sale423.6711,1734,733,66520,029Feb 25 04:01 PM
Terifay Robert JSVP CommercialFeb 23Option Exercise30.6324,375746,60644,404Feb 25 04:01 PM
Aberman Michael SSVP Strategy Investor RelationFeb 23Option Exercise30.637,500229,72526,100Feb 25 04:02 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 23Sale427.829,4314,034,75418,705Feb 24 05:08 PM
RYAN ARTHUR FDirectorFeb 20Option Exercise125.7929,2503,679,49876,750Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Option Exercise57.111,00057,1101,000Feb 23 04:07 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 20Option Exercise21.2520,000425,00038,705Feb 24 05:08 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Option Exercise177.825,000889,1009,000Feb 20 04:44 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale423.655,0002,118,2624,000Feb 20 04:44 PM
BROWN MICHAEL SDirectorFeb 20Sale422.721,000422,7200Feb 23 04:07 PM
RYAN ARTHUR FDirectorFeb 20Sale423.0129,25012,372,90847,500Feb 23 04:06 PM
Aberman Michael SSVP Strategy Investor RelationFeb 17Sale404.463,6921,493,26618,600Feb 18 04:40 PM
Aberman Michael SSVP Strategy Investor RelationFeb 13Option Exercise24.007,500180,00026,100Feb 18 04:40 PM
SCHLEIFER LEONARD SPresident & CEOJan 02Sale410.581,500615,8670Jan 05 04:56 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale414.0810,8224,481,21410,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise52.0325,0001,300,75035,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 19Option Exercise30.633,26499,97610,711Dec 22 12:09 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise30.633,26499,97618,705Dec 19 02:11 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 17Option Exercise30.632,80085,7647,481Dec 18 04:22 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 16Option Exercise30.633,26499,97664,436Dec 18 04:25 PM
STAHL NEILSVP Research and Development SDec 16Option Exercise30.633,26499,9766,541Dec 18 04:25 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise30.633,26499,976503,264Dec 18 04:23 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise49.076,818334,56010,556Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Sale410.006,8182,795,3804,681Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Option Exercise30.631,66851,0916,049Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Sale410.761,668685,1444,681Dec 17 04:51 PM
POON CHRISTINE ADirectorNov 25Buy410.00400164,000655Nov 26 01:28 PM
GILMAN ALFRED GDirectorNov 24Option Exercise35.9640,0001,438,55040,000Nov 25 04:16 PM
GILMAN ALFRED GDirectorNov 24Sale408.4440,00016,337,5850Nov 25 04:16 PM
STAHL NEILSVP Research and Development SNov 24Sale409.782,200901,5233,277Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 21Sale415.163,1071,289,9025,477Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 18Option Exercise115.2916,7571,931,91530,284Nov 20 04:14 PM
Terifay Robert JSVP CommercialNov 18Sale405.7922,3629,074,20020,029Nov 19 04:41 PM
Terifay Robert JSVP CommercialNov 17Option Exercise21.2548,7501,035,93868,779Nov 19 04:41 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 13Sale399.348,5753,424,33615,441Nov 14 04:32 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 12Option Exercise21.2518,700397,37534,141Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Option Exercise177.825,000889,1009,000Nov 12 05:15 PM
GOLDSTEIN JOSEPH LDirectorNov 12Sale398.315,0001,991,5504,000Nov 12 05:15 PM
SCHLEIFER LEONARD SPresident & CEONov 12Sale400.3242,32416,943,28542,087Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEONov 11Sale400.003,4931,397,20084,411Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 31Sale400.113,4531,381,58087,904Nov 04 04:06 PM
SCHLEIFER LEONARD SPresident & CEOOct 28Sale404.0169,11227,921,80691,357Oct 29 04:27 PM
SCHLEIFER LEONARD SPresident & CEOOct 27Option Exercise19.40256,8084,982,219292,893Oct 29 04:27 PM
BROWN MICHAEL SDirectorOct 24Option Exercise57.115,000285,5505,000Oct 24 04:07 PM
BROWN MICHAEL SDirectorOct 24Sale399.005,0001,995,0000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 24Sale400.7026,78810,734,01863,102Oct 27 04:17 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 23Option Exercise30.6360,0001,837,800123,102Oct 27 04:17 PM
VAGELOS P ROYChairman of the BoardSep 10Sale350.0710,3263,614,82392,947Sep 10 04:00 PM
VAGELOS P ROYChairman of the BoardSep 08Sale351.002702103,273Sep 10 04:00 PM